Black Diamond Therapeutics Email Format

Biotechnology ResearchMassachusetts, United States11-50 Employees

Black Diamond Therapeutics is a clinical-stage biotechnology company focused on oncology. It develops therapies designed to target families of oncogenic mutations to broaden the patient population by offering one solution for multiple mutations, with the aim of overcoming resistance to cancer treatments and extending patients' lives. The company is based in Cambridge, Massachusetts, and is advancing silevertinib, a brain-penetrant fourth-generation EGFR inhibitor for non-small cell lung cancer and glioblastoma.

It has a licensing collaboration with Servier to develop BDTX-4933 for RAF- and RAS-mutant solid tumors, including NSCLC. In 2026 the company has announced participation in major oncology events, including the Jefferies Global Healthcare Conference and the ASCO Annual Meeting, reflecting ongoing clinical activity.

Sign up for free to view info

Company overview Employee directory